Redeye comments on Carasent’s Q4 report, showing slightly lower organic ARR growth yet solid scalability. We retain our positive view and will likely leave our forecasts and Base Case largely unchanged.
ANNONS
Redeye comments on Carasent’s Q4 report, showing slightly lower organic ARR growth yet solid scalability. We retain our positive view and will likely leave our forecasts and Base Case largely unchanged.
